Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

por Kümler, I., Sørensen, P. Grundtvig, Palshof, J., Høgdall, E., Skovrider-Ruminski, W., Theile, S., Fullerton, A., Nielsen, P. G., Jensen, B. Vittrup, Nielsen, D. L.
Publicado 2018